[ Price : $8.95]
FDA warns Osmed GmbH about Quality System and other violations in its manufacturing of a tissue expander.[ Price : $8.95]
FDAs Los Angeles District Office warns Crescendo Therapeutics of post-marketing adverse drug experience and unapproved new drug vi...[ Price : $8.95]
FDA has accepted for review a Bristol-Myers Squibb/Pfizer NDA for Eliquis for preventing stroke and systemic embolism in atrial fi...[ Price : $8.95]
BioTime and subsidiary OncoCyte appoint former FDA commissioner Andrew von Eschenbach to their boards of directors.[ Price : $8.95]
FDAs New Jersey District Office releases an FDA-483 detailing eight violations found at Integra LifeSciences.[ Price : $8.95]
FDA says it will review an Onyx NDA for carfilzomib to treat some patients with multiple myeloma.[ Price : $8.95]
FDA releases an FDA-483 detailing 10 inspectional observations made at Zimmer, Inc.[ Price : $8.95]
In its latest batch of Warning Letters, FDA cites Crescendo Therapeutics, Hills Pet Nutrition, Nanoliposomals, Osmed, and Precisio...